Company news
Rhelion Life Sciences Corp. news in 2026
Rhelion Life Sciences Corp.'s news releases, calls and decks from 2026, newest first.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial
November 3, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing
November 2, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
October 28, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
October 16, 2026
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
October 14, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
October 8, 2026
Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences
July 29, 2026
Red Light Holland Announces New Filament Health PEX010 European Research Shipment
July 16, 2026
Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
July 8, 2026
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
July 7, 2026
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health
June 18, 2026
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France
June 8, 2026
Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
May 25, 2026
Red Light Holland: Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health’s GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
May 24, 2026
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
May 13, 2026
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
May 7, 2026
Red Light Holland Announces Intention to Rebrand
May 4, 2026
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
April 30, 2026
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
April 29, 2026
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
April 27, 2026
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
April 24, 2026
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
April 20, 2026
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
April 7, 2026
Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network
April 1, 2026
Tripadvisor and Starboard Value Enter into Cooperation Agreement
March 23, 2026
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
March 23, 2026
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
March 18, 2026
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
March 18, 2026
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
March 10, 2026
Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
March 3, 2026
Wanderlab at Tripadvisor and Choice Hotels International Launch Ultimate Route 66 Road Trip Guide Ahead of Historic 100-Year Celebration
February 24, 2026
Top Beaches 2026: Tripadvisor Travelers' Choice Awards World's Best
February 17, 2026
Correction: Tripadvisor
January 13, 2026